Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Zimmer Biomet Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Zimmer Biomet Holdings Inc trades at $87.68 (market cap $17.30B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.9× ACADIA Pharmaceuticals Inc.'s market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ZBH | |
|---|---|---|
Market Cap | $4.49B | $17.30B |
Sector | Health | Health |
52-Week High | $28.06 | $107.71 |
52-Week Low | $20.06 | $79.58 |
Enterprise Value | $3.69B | $24.34B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Zimmer Biomet (ZBH) trades at $89.41, up 2.22% with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with 70% gross margins and revenue growth to $8.23B in 2025, though net margins compressed to 8.56%. Recent developments include a $140M acquisition and plans to hire 500 tech employees in India, supporting growth initiatives. Valuation metrics appear reasonable with P/E of 23.25 and P/S of 2.11.
ZBH offers moderate upside to the $98.33 consensus target with analyst sentiment mixed (43% buy, 50% hold). Key risks include rising debt levels (debt-to-asset ratio increased to 32.57% in 2025) and margin pressure. The company's $1B share repurchase program and dividend provide shareholder returns, but execution on growth initiatives remains critical for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
